Pfizer and BioNTech have signed a new supply agreement with the European Commission (EC) for 900 million doses of Comirnaty, the companies’ Covid-19 vaccine, to the European Union (EU). The EC has the option to request an extra 900 million doses. The new deal is in addition to the 600 million doses already committed to the EU through 2021. The 900 million doses are expected to be delivered between December 2021 and 2023.

The Canadian government, through the Covid-19 Immunity Task Force (CITF) and the Vaccine Surveillance Reference Group (VSRG),  is supporting a new $4.8m nation-wide study that will analyse the effects of mixing and matching authorised Covid-19 vaccines in adults. The study will focus on examining the safety and efficacy of using two different Covid-19 vaccines for the first and second dose.  The project will also assess the effects of increasing the intervals between the two doses.

Biopharmaceutical company Immunome has been awarded an additional $4.3m by the US Department of Defence (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defence (JPEO-CBRND), in partnership with the Defence Health Agency (DHA), for continuing the development of its antibody cocktail (IMM-BCP-01) to fight Covid-19 and its variants. The DOD had awarded $13.3m to the company to develop the antibody cocktail a year ago. IMM-BCP-01 contains three monoclonal antibodies that exhibit combinatorial effects in vitro against multiple SARS-CoV-2 variants.